2007
DOI: 10.1152/ajprenal.00327.2005
|View full text |Cite
|
Sign up to set email alerts
|

Effect of combination therapy with enalapril and the TGF-β antagonist 1D11 in unilateral ureteral obstruction

Abstract: Poppas DP, Felsen D. Effect of combination therapy with enalapril and the TGF-␤ antagonist 1D11 in unilateral ureteral obstruction.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
38
0

Year Published

2010
2010
2021
2021

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 55 publications
(41 citation statements)
references
References 40 publications
3
38
0
Order By: Relevance
“…12 Hence, mice were treated with 200 mg/L of the angiotensin converting enzyme inhibitor enalapril 13 continuously in the drinking water after FA injection. This resulted in reduced kidney fibrosis development by .33% at day 14, as indicated by histologic assessment ( Figure 4, E and F) and an approximate three-fold reduction of Col1a1 and Fn1 mRNA expression ( Figure 4G).…”
Section: Protein Expression Of the Candidates After Kidney Fibrosis Imentioning
confidence: 99%
“…12 Hence, mice were treated with 200 mg/L of the angiotensin converting enzyme inhibitor enalapril 13 continuously in the drinking water after FA injection. This resulted in reduced kidney fibrosis development by .33% at day 14, as indicated by histologic assessment ( Figure 4, E and F) and an approximate three-fold reduction of Col1a1 and Fn1 mRNA expression ( Figure 4G).…”
Section: Protein Expression Of the Candidates After Kidney Fibrosis Imentioning
confidence: 99%
“…Increased TGF-β1 mRNA and protein expression after CsA treatment suggests a role for TGF-β1 in the current model, and this is in agreement with previous studies (Shihab et al, 2003;Shihab et al, 2006;Lloberas et al, 2008). However, despite some initially promising results in experimental models of CsA nephropathy (Ling et al, 2003;El Chaar et al, 2007), TGF-β1 blockade has not yet translated into an effective therapeutic strategy in human patients. Both CTGF and BMP-7 are downstream modulators of TGF-β1 signalling (Veerasamy et al, 2009; A C C E P T E D M A N U S C R I P T of TIF (Ito et al, 1998;Gupta et al, 2000;Yokoi et al, 2002;Wang and Hirschberg, 2003).…”
Section: Accepted M Manuscriptmentioning
confidence: 99%
“…In these animals, gene expression of the angiotensin II type 1 (AT 1 ) receptor and the binding affinity of angiotensin II with the AT 1 receptor in the kidney were also increased (20). Treatment with the AT 1 -receptor blockers (21) or angiotensinconverting enzyme (ACE) inhibitors (22) is known to ameliorate UUO-induced renal injury in mice and rats. Other studies have shown that UUO-induced renal fibrosis is reduced in mice lacking angiotensinogen (23) or the AT 1a receptor (24).…”
Section: Introductionmentioning
confidence: 99%